---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-24-000007"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:44:57.113031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024

## Summary
- Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.
- Raised $180M gross from private placement; cash runway into H2 2026.
- SPY001 anti-α4β7 shows 22-day half-life (3x vedolizumab); FIH studies expected H1 2024 with interim data year-end.
- SPY002 anti-TL1A candidates nominated; preclinical half-life 24 days (2-3x clinical-stage); FIH in H2 2024.
- Appointed CEO Cameron Turtle and board member Mark McKenna; name changed to Spyre Therapeutics.

## SEC filing metadata
- accession: 0001636282-24-000007
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/0001636282-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/agle-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-24-000007
- JSON: https://secwatch.observer/filing/0001636282-24-000007.json
- Plain text: https://secwatch.observer/filing/0001636282-24-000007.txt

## Key facts
- Earnings Releases
  Spyre Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/0001636282-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.